Pseudocystic foveal cavitation in tamoxifen retinopathy.
暂无分享,去创建一个
[1] B. J. Klevering,et al. Multimodal imaging of the macula in hereditary and acquired lack of macular pigment , 2014, Acta ophthalmologica.
[2] S. Barni,et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials , 2013, Breast Cancer Research and Treatment.
[3] I. Georgalas,et al. Large bilateral foveal cysts in the inner retina of a patient treated with tamoxifen, diagnosed with Fourier-domain optical coherence tomography , 2013, Clinical ophthalmology.
[4] A. Nair,et al. The eyes have it! Tamoxifen maculopathy revisited: a case report. , 2012, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[5] David Williams,et al. Retinal crystals in type 2 idiopathic macular telangiectasia. , 2010, Ophthalmology (Rochester, Minn.).
[6] R. Guymer,et al. Perifoveal müller cell depletion in a case of macular telangiectasia type 2. , 2010, Ophthalmology.
[7] H. Chung,et al. Estrogen Antagonist and Development of Macular Hole , 2010, Korean journal of ophthalmology : KJO.
[8] Nirmala Srikantia,et al. Crystalline maculopathy: a rare complication of tamoxifen therapy. , 2010, Journal of cancer research and therapeutics.
[9] S. Ahn,et al. Early Detection of Tamoxifen-induced Maculopathy in Patients With Low Cumulative Doses of Tamoxifen. , 2010, Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye.
[10] J. Sallum,et al. Retinal function in patients treated with tamoxifen , 2010, Documenta Ophthalmologica.
[11] R. Zawadzki,et al. Microcystoid maculopathy associated with tamoxifen use diagnosed by high-resolution fourier-domain optical coherence tomography. , 2009, Retinal cases & brief reports.
[12] Julie Brown,et al. Clomiphene and anti-oestrogens for ovulation induction in PCOS. , 2009, The Cochrane database of systematic reviews.
[13] H. Scholl,et al. ABNORMAL MACULAR PIGMENT DISTRIBUTION IN TYPE 2 IDIOPATHIC MACULAR TELANGIECTASIA , 2008, Retina.
[14] P. Bernstein,et al. Diagnostic & therapeutic challenges. Tamoxifen toxicity. , 2007, Retina.
[15] D. Sarraf,et al. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. , 2007, American journal of ophthalmology.
[16] A. Berezovsky,et al. Multifocal Electroretinography, Color Discrimination and Ocular Toxicity in Tamoxifen Use , 2007, Current eye research.
[17] Peter Wiedemann,et al. Müller cells in the healthy and diseased retina , 2006, Progress in Retinal and Eye Research.
[18] Mauget-Faÿsse Martine,et al. Optical coherence tomography in tamoxifen retinopathy , 2006, Breast Cancer Research and Treatment.
[19] A. Eisner,et al. Small Optic Cup Sizes Among Women Using Tamoxifen: Assessment with Scanning Laser Ophthalmoscopy , 2006, Current eye research.
[20] R. Bourke,et al. Tamoxifen therapy conveys increased risk of developing a macular hole , 2006, International Ophthalmology.
[21] J. Sahel,et al. Optical coherence tomography findings in tamoxifen retinopathy. , 2005, American journal of ophthalmology.
[22] Wei Zhang,et al. Agents with Selective Estrogen Receptor (ER) Modulator Activity Induce Apoptosis In vitro and In vivo in ER-Negative Glioma Cells , 2004, Cancer Research.
[23] K. Holli,et al. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. , 2003, Acta ophthalmologica Scandinavica.
[24] L. Salminen,et al. Glutamate uptake is inhibited by tamoxifen and toremifene in cultured retinal pigment epithelial cells. , 2002, Pharmacology & toxicology.
[25] C. Flaxel,et al. Intraocular penetration of tamoxifen. , 2000, Ophthalmology.
[26] M. Seoud,et al. Ocular toxicity in low-dose tamoxifen: A prospective study , 1999, Eye.
[27] G. Savini,et al. Tamoxifen retinopathy: does it really exist? , 1998, Graefe's Archive for Clinical and Experimental Ophthalmology.
[28] L. Mastronardi,et al. Tamoxifen as a potential treatment of glioma. , 1998, Anti-cancer drugs.
[29] C. Redmond,et al. Long-term tamoxifen citrate use and potential ocular toxicity. , 1998, American journal of ophthalmology.
[30] Helen K. Li,et al. Retinal changes associated with tamoxifen treatment for breast cancer , 1997, Eye.
[31] M. Gorin,et al. Tamoxifen-associated eye disease. A review. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] A. Leys,et al. Screening for Tamoxifen Ocular Toxicity: A Prospective Study , 1995, European journal of ophthalmology.
[33] R. Enzenauer,et al. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. , 1994, American journal of ophthalmology.
[34] N. Pavlidis,et al. Clear evidence that long‐term, low‐dose tamoxifen treatment can induce ocular toxicity a prospective study of 63 patients , 1992, Cancer.
[35] H. Sigurdsson,et al. A controlled study of the ocular effects of tamoxifen in conventional dosage in the treatment of breast carcinoma. , 1989, European journal of cancer & clinical oncology.
[36] T. Vinding,et al. RETINOPATHY CAUSED BY TREATMENT WITH TAMOXIFEN IN LOW DOSAGE , 1983, Acta ophthalmologica.
[37] M. Kaiser-Kupfer,et al. 1. Tamoxifen Retinopathy: A Clinicopathologic Report , 1981 .
[38] P. Mills,et al. Ocular assessment of patients treated with tamoxifen. , 1979, Cancer treatment reports.
[39] The Reflexes of the Fundus Oculi , 1940 .